Regenxbio Inc   (RGNX)
Other Ticker:  
Price: $18.6100 $-0.61 -3.174%
Day's High: $19.885 Week Perf: -2.72 %
Day's Low: $ 18.55 30 Day Perf: 29.51 %
Volume (M): 554 52 Wk High: $ 25.54
Volume (M$): $ 10,301 52 Wk Avg: $19.55
Open: $19.30 52 Wk Low: $12.82

 Market Capitalization (Millions $) 817
 Shares Outstanding (Millions) 44
 Employees 300
 Revenues (TTM) (Millions $) 99
 Net Income (TTM) (Millions $) -261
 Cash Flow (TTM) (Millions $) -65
 Capital Exp. (TTM) (Millions $) 14

Regenxbio Inc
Regenxbio Inc is a leading biotechnology company, headquartered in Maryland, USA.
The company specializes in developing gene therapies for the treatment of genetic diseases.
Established in 2008, Regenxbio has quickly gained recognition for its innovative approach in the field of gene therapy.
The company uses proprietary viral vectors to deliver genes to specific cells in the body, aiming to correct the genetic defects that cause various diseases.
Regenxbio's gene therapy approach holds promise for the treatment of a range of genetic disorders, including rare diseases.
Regenxbio currently has several gene therapy candidates under development, targeting different disorders, including Angelman syndrome, Huntington's disease, and retinal disorders.
The company's lead candidate, RGX-314, is being developed for the treatment of wet age-related macular degeneration (AMD).
RGX-314 has already shown impressive results in clinical trials, demonstrating its potential as a game-changer for the treatment of AMD.
In addition to its gene therapy pipeline, Regenxbio has collaborations with several leading biotech and pharmaceutical companies.
These collaborations are aimed at leveraging Regenxbio's technology to develop new gene therapies for various indications, including neurodegenerative diseases and cancer.
Regenxbio has a team of experienced professionals, including scientists, researchers, and medical experts.
The company's leadership team is composed of industry experts, and its board of directors includes renowned physicians, scientists, and business leaders.
Regenxbio has received significant funding from several venture capital firms and investors.
Overall, Regenxbio Inc is a promising biotechnology company that is at the forefront of developing gene therapies for the treatment of various genetic diseases.
With its strong pipeline of gene therapy candidates and collaborations with leading partners, the company is well-positioned for long-term growth and success.

   Company Address: 9804 Medical Center Drive Rockville 20850 MD
   Company Phone Number: 552-8181   Stock Exchange / Ticker: NASDAQ RGNX
   RGNX is expected to report next financial results on February 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Semper Paratus Acquisition Corporation

The arising business from the Biotechnology and Pharmaceuticals market the LGST published the fiscal third quarter of 2023, numbers

The Biotechnology and Pharmaceuticals sector experts continue to interpret the third quarter of 2023 earnings. Presently those experts observe operating deficit of $-0.605971 million, from the Semper Paratus Acquisition Corporation, which has not cited any top-line so far, for the own July to September 30 2023 quarter.

Ladrx Corporation

Ladrx Corporation's Fiscal Report Reveals Operating Shortfall of $-0.840313 Million in Biotechnology and Pharmaceuticals Sector for September 2023

The stock market is an ever-evolving landscape, filled with opportunities for both investors and corporations alike. In the Biotechnology and Pharmaceuticals sector, some companies often go unnoticed, but they are now emerging with promising earnings. One such corporation is Ladrx Corporation, which recently reported a decrease in its operating shortfall for the third quarter of 2023.
In comparison to the third quarter of 2022, Ladrx Corporation's operating shortfall has significantly improved. Last year, the company experienced an operating shortfall of $-1.167527 million. However, this year, the shortfall has decreased to $-0.840313 million. These numbers serve as crucial signals for the state of Ladrx Corporation, indicating a positive trend in the company's financial performance.

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc's Trailblazing Journey: Overcoming a Surprising $-0.04 per Share Loss Amidst the Fiscal Time-frame Ending September 30, 2023

For the fiscal time-frame ending September 30 2023 LCTX lost money of $-0.04 per share compare to $-0.04 a year before and surged loss from $-0.03 per share from the previous quarter. The revenue fell sharply by -58.439 % to $1.25 million from $3.00 million in the comparable quarter a year before and sequentially Revenue Tumbled by -61.364 % from $3.23 million.

Bio Techne Corp

Reduction in Earnings while revenue grew in the July to September 30 2023 fiscal time-frame

Revenue improvement of 2.447 %, could not prevent income decline of -85.97 % in the most recent fiscal period, relative to comparable reporting period a year before. revenue were at $276.19 million and eps at $0.31.

Anavex Life Sciences Corp

Anavex Life Sciences Corp's EPS Soars by 454.76% Despite Decline in Revenue during Q4 2023

Date: November 30, 2023
Anavex Life Sciences Corp, a renowned Biotechnology and Pharmaceuticals company, recently reported its financial results for the fiscal fourth quarter of 2023. Despite a sharp decline in revenue, the company's earnings per share (EPS) witnessed a commendable surge. Let's delve into the details of these results and analyze what this means for the future of the company.
In the fiscal fourth quarter of 2023, Anavex Life Sciences Corp reported a staggering EPS growth of 454.76%. The EPS rose to $0.48 per share, compared to $0.09 per share in the same quarter a year ago. Moreover, the company was able to turn its EPS positive, bouncing back from a loss of $-0.14 per share in the prior quarter. This robust growth in earnings is undoubtedly a positive sign for shareholders and investors.


Regenxbio Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com